Active pharmaceutical ingredients (APIs) are the key components in pharmaceutical drugs that produce their intended therapeutic effects, making them essential elements in the development and manufacturing of medicines. However, producing these APIs under full cGMP conditions with speed, efficiency, and quality is a complex undertaking.
From initial research and development to regulatory compliance and scale-up production, biotechnology and pharmaceutical companies face numerous challenges. Thankfully, industry-leading CDMO partners can support these drug developers during pre-clinical, clinical, and commercial phases, ultimately accelerating time to market for small molecules.
At Thermo Fisher Scientific, we were involved in manufacturing 16% of all small molecules approved by the FDA in 2023, and we have over 50 years of experience in API development and manufacturing. To provide a comprehensive overview of our API capabilities, we’ve developed a brochure that outlines our end-to-end development and manufacturing services.
Specifically, the brochure’s contents include:
Download the brochure to learn more.